While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its ...

An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease ...

Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

2017-010 Natural History Study Of The Development Of Type 1 Diabetes (Trialnet TN01) Blood draw to determine if a patient may be a risk factor for patients with a family history of Type 1 Diabetes.

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Under the new law, anyone in Montana can legally access drugs that have passed just one phase 1 clinical trial.

The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...